<DOC>
	<DOCNO>NCT00934921</DOCNO>
	<brief_summary>The objective study compare relative bioavailability test formulation Ondansetron HCl already market reference formulation ZofranÂ® ODT non-fasting condition healthy , non-smoking , adult subject .</brief_summary>
	<brief_title>Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>All subject select study nonsmoker least 18 year age . Subjects BMI ( body mass index ) 30 less . Subjects significant recent history chronic alcohol consumption , drug addiction , serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma eligible study . Subjects whose clinical laboratory test value great 20 % outside normal range may retested . If clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant . Subjects history allergic response class drug test exclude study . Subjects use tobacco form eligible participate study . Three month abstinence require . All subject urine sample assay presence drug abuse part clinical laboratory screening procedure dose period checkin . Subjects found urine concentration test drug allow participate . Subjects donate blood and/or plasma least thirty ( 30 ) day prior first dose study . Subjects take investigational drug within thirty ( 30 ) day prior first dose study allow participate . Female subject pregnant , breastfeeding , likely become pregnant study allow participate . Female subject child bear potential must either abstain sexual intercourse use reliable barrier method ( e.g . condom , IUD ) contraception course study ( first dose last blood collection ) allow participate . Subjects use implant injected hormonal contraceptive anytime 180 day prior study dose oral hormonal contraceptive 14 day dose allowed participate . All Female subject screen pregnancy checkin study period . Subjects positive inconclusive result withdrawn study . Subjects tolerate venipuncture allow participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>